These findings were also confirmed using mRNA expression analysis, suggesting that co‐expression of HER2 with ATM factors may be potential molecular biomarkers for predicting bladder cancer prognosis and disease aggressiveness. This evidence concerns the gene ERBB2 and urinary bladder cancer.